Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
AssigneeUniversitäT ZüRich
InventorsBurkhard Becher, Johannes Vom Berg
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
Claims9
A method of treating a patient suffering from a malignant tumor, wherein the malignant tumor is melanoma, the method comprising
- a. administering into the malignant tumor, the vicinity of the malignant tumor, or the lymph node associated with the malignant tumor, an effective amount of
- a recombinant IL-12 polypeptide comprising
- i. a human IL-12 p35 comprising the amino acid sequence SEQ ID NO:5,
- ii. a human IL-12 p40 comprising the amino acid sequence SEQ ID NO:6 and
- iii. optionally, a human immunoglobulin G crystallisable fragment;
- and
- b. systemically administering an effective amount of a non-agonist blockade of T-cell inhibitory antibody, wherein the antibody is an anti-PD-1 antibody, thereby treating the malignant tumor.
A method of treating a patient suffering from a malignant tumor, wherein the malignant tumor is melanoma, the method comprising
- a. administering into the malignant tumor, the vicinity of the malignant tumor, or the lymph node associated with the malignant tumor, an effective amount of
- a recombinant IL-12 polypeptide comprising the amino acid sequence SEQ ID NO:
- 1,
- and
- b. systemically administering an effective amount of an anti-PD-1 antibody, thereby treating the malignant tumor.
Dependencies are inferred from the claim text.